Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition

Journal of Molecular Recognition

Volumn 26, Issue 9, 2013, Pages 432-438

  Li, Mi ^a,b   Xiao, Xiubin ^c   Liu, Lianqing ^a   Xi, Ning ^a,d   Wang, Yuechao ^a   Dong, Zaili ^a   Zhang, Weijing ^c  

^a SHENYANG INSTITUTE OF AUTOMATION   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

atomic force microscopy; CD20; lymphoma; rituximab; ROR1; single molecule force spectroscopy

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; IMMOBILIZED ANTIBODY; MONOCLONAL ANTIBODY; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; RITUXIMAB; ROR1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; ATOMIC FORCE MICROSCOPY; CD20; CELL SHAPE; CHEMISTRY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOMA; METABOLISM; PATHOLOGY; PROTEIN BINDING; ROR1; SINGLE-MOLECULE FORCE SPECTROSCOPY; TUMOR CELL LINE;

ATOMIC FORCE MICROSCOPY; CD20; LYMPHOMA; RITUXIMAB; ROR1; SINGLE-MOLECULE FORCE SPECTROSCOPY;

ANTIBODIES, IMMOBILIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SHAPE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LYMPHOMA, FOLLICULAR; MICROSCOPY, ATOMIC FORCE; PROTEIN BINDING; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880093997     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2287     Document Type: Article

References (32)

1. Alduaij W, Illidge TM,. 2011. The future of anti-CD20 monoclonal antibodies: are we making progress. Blood 117: 2993-3001.
2. Barna G, Mihalik R, Timar B, Tombol J, Csende Z, Sebestyen A, Bodor C, Csernus B, Reiniger L, Petak I, Matolcsy A,. 2011. ROR1 expression is not a unique marker of CLL. Hematol. Oncol. 29: 17-21.
3. Binnig G, Quate CF, Gerber C,. 1986. Atomic force microscope. Phys. Rev. Lett. 56: 930-933.
4. Carter PJ,. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357.
5. Cartron G, Watier H, Golay J, Solal-Celigny P,. 2004. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642.
6. Carvalho FA, Connell S, Miltenberger-Miltenyi G, Pereira SV, Tavares A, Ariens RAS, Santos NC,. 2010. Atomic force microscopy-based molecular recognition of a fibrinogen receptor on human erythrocytes. ACS Nano 4: 4609-4620.
7. Casuso I, Rico F, Scheuring S,. 2011. Biological AFM: where we come from-where we are-where we may go. J. Mol. Recognit. 24: 406-413.
8. Cheson BD, Leonard JP,. 2008. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med. 359: 613-626.
9. Dufrene YF, Evans E, Engel A, Helenius J, Gaub HE, Muller DJ,. 2011. Five challenges to bringing single-molecule force spectroscopy into living cells. Nat. Methods 8: 123-127.
10. Dupres V, Alsteens D, Andre G, Verbelen C, Dufrene YF,. 2009. Fishing single molecules on live cells. Nano Today 4: 262-268.
11. Florin EL, Moy VT, Gaub HE,. 1994. Adhesion forces between individual ligand-receptor pairs. Science 264: 415-417.
12. Glennie MJ, French RR, Cragg MS, Taylor RP,. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
13. Hinderdorfer P, Baumgartner W, Gruber HJ, Schilcher K, Schindler H,. 1996. Detection and localization of individual antibody-antigen recognition events by atomic force microscopy. Proc. Natl. Acad. Sci. U.S.A. 93: 3477-3481.
14. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR,. 2010. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116: 4532-4541.
15. Hutter JL, Bechhoefer J,. 1993. Calibration of atomic-force microscope tips. Rev. Sci. Instrum. 64: 1868-1873.
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59: 225-249.
17. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. 2011. Global cancer statistics. CA Cancer J. Clin. 61: 69-90.
18. Lee C K, Wang Y M, Huang L S, Lin S,. 2007. Atomic force microscopy: determination of unbinding force, off rate and energy barrier for protein-ligand interaction. Micron 38: 446-461.
19. Li M, Liu L, Xi N, Wang Y, Dong Z, Li G, Xiao X, Zhang W,. 2011. Detecting CD20-rituximab interaction forces using AFM single-molecule force spectroscopy. Chinese Sci. Bull. 56: 3829-3835.
20. Li M, Xiao X, Liu L, Xi N, Wang Y, Dong Z, Zhang W,. 2013. Imaging and measuring the molecular force of lymphoma pathological cells using atomic force microscopy. Scanning 35: 40-46.
21. Lim SH, Beers SA, French RR, Johnson PWM, Glennie MJ, Cragg MS,. 2010. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95: 135-143.
22. Marshall BT, Long M, Piper JW, Yago T, McEver RP, Zhu C,. 2003. Direct observation of catch bonds involving cell-adhesion molecules. Nature 423: 190-193.
23. Muller DJ, Helenius J, Alsteens D, Dufrene YF,. 2009. Force probing surfaces of living cells to molecular resolution. Nat. Chem. Biol. 5: 383-390.
24. Oflazoglu E, Audoly LP,. 2010. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2: 14-19.
25. Rebagay G, Yan S, Liu C, Cheung NK,. 2012. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front. Oncol. 2: 34.
26. Rezvani AR, Maloney DG,. 2011. Rituximab resistance. Best Pract. Res. Clin. Haematol. 24: 203-216.
27. Sawyers CL,. 2008. The cancer biomarker problem. Nature 452: 548-552.
28. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y,. 2010. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24: 1760-1768.
29. Uhrmacher S, Schmidt C, Erdfelder F, Poll-Wolbeck SJ, Gehrke I, Hallek M, Kreuzer KA,. 2011. Use of the receptor tyrosine kinase-like orphan receptor 1(ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk. Res. 35: 1360-1366.
30. Yamada KM, Cukierman E,. 2007. Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610.
31. Zhang J, Wu G, Song C, Li Y, Qiao H, Zhu P, Hinterdorfer P, Zhang B, Tang J,. 2012a. Single molecular recognition force spectroscopy study of a lutheinizing hormone-releasing hormone analogue as a carcinoma target drug. J. Phys. Chem. B 116: 13331-13337.
32. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ,. 2012b. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181: 1903-1910.